Syringe with viscoelastic agent chamber and decomposition agent chamber for ocular manipulation

By designing an syringe containing viscoelastic agent and disintegrating agent, the increased operational complexity caused by injecting viscoelastic agent and disintegrating agent separately in the prior art is solved, achieving simplified eye operation and effective disintegration of viscoelastic agent, and reducing the risk of increased intraocular pressure.

CN121038832APending Publication Date: 2025-11-28CARL ZEISS MEDITEC AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202480029676.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-12
Filing Date
2024-04-24
Publication Date
2025-11-28

AI Technical Summary

Technical Problem

In eye procedures, existing techniques require separate injections of viscoelastic agents and disintegrating agents, increasing the complexity of the procedure. Furthermore, low-viscosity dispersible viscoelastic agents are difficult to remove from the eye, which may lead to increased intraocular pressure.

Method used

Design a syringe comprising a viscoelastic chamber and a decomposing reagent chamber, wherein the plunger can be moved in the longitudinal direction, the viscoelastic and decomposing reagent are separated in the storage state, and are mixed and injected in the use state, thus avoiding mixing in the storage state.

Benefits of technology

The procedure for handling the eye has been simplified, ensuring that the viscoelastic agent functions before it decomposes, reducing the number of steps and avoiding the risk of the viscoelastic agent clogging the trabecular meshwork of the eye.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121038832A_ABST
    Figure CN121038832A_ABST
Patent Text Reader

Abstract

The invention relates to a syringe (1) for ocular operation, comprising: a syringe body (3); a plunger (4) arranged in the syringe body so as to be displaceable in the syringe longitudinal direction (5); a viscoelastic agent chamber (6) in which a viscoelastic agent is arranged; the invention relates to a syringe (1) comprising a viscoelastic chamber (6), and a disintegration reagent chamber (7) arranged separately from the viscoelastic chamber (6) and in which a disintegration reagent designed to disintegrate the viscoelastic agent is arranged, the syringe (1) having a storage state in which the viscoelastic agent and the disintegration reagent are arranged separately from one another and a use state in which the viscoelastic agent and the disintegration reagent are arranged separately from one another. The syringe (1) can be brought into the use state by longitudinal displacement of the plunger (4), and in the use state, the viscoelastic agent and the decomposition agent are mixed with each other.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a syringe for eye operation, wherein the syringe includes a viscoelastic chamber and a dissolving reagent chamber. Background Technology

[0002] In ophthalmic procedures, particularly cataract treatment, viscoelastic agents are commonly introduced into the eye. These agents may, for example, contain sodium hyaluronate. Viscoelastic agents can be high-viscosity cohesive viscoelastics, used to maintain intraocular space and build pressure, for example, to dilate the iris before capsulorhexis. They can also be low-viscosity dispersive viscoelastics, which wet the surfaces within the eye to protect them from damage during the procedure. Viscoelastic agents must be removed from the eye at the end of the procedure because they can obstruct the trabecular meshwork, potentially leading to increased intraocular pressure. In particular, low-viscosity dispersive viscoelastics wet the cornea and iridocorneal angle. Because these areas may be difficult to reach with a suction probe, low-viscosity dispersive viscoelastics can also be difficult to remove from the eye. Injection of hyaluronidase into the eye is known. Hyaluronidase is an agent that breaks down sodium hyaluronate. Therefore, it is necessary to provide a syringe containing hyaluronidase during the procedure and to introduce the syringe into the eye for the injection of hyaluronidase. This is an additional step that needs to be performed by the physician performing the eye procedure, making the procedure more complex. Summary of the Invention

[0003] Therefore, the object of the present invention is to provide a syringe that is not complicated to operate with the eye.

[0004] The syringe for eye manipulation according to the present invention includes a syringe body, a plunger, a viscoelastic chamber, and a dissolving reagent chamber. The plunger is arranged in the syringe body to be displaceable in the longitudinal direction of the syringe. The viscoelastic is arranged in the viscoelastic chamber. The dissolving reagent chamber is arranged separately from the viscoelastic chamber, and a dissolving reagent configured to dissolve the viscoelastic is arranged in the dissolving reagent chamber. The syringe has a storage state and a use state, in which the viscoelastic and the dissolving reagent are arranged separately from each other, the syringe being capable of entering the use state by longitudinal displacement of the plunger, and in which the viscoelastic and the dissolving reagent are mixed together.

[0005] With the syringe according to the invention, it is unnecessary to provide a separate syringe for the dissolving agent; instead, the syringe according to the invention provides both the viscoelastic agent and the dissolving agent. Therefore, eye manipulation using this syringe is less complicated. In the storage state, mixing of the viscoelastic agent and the dissolving agent is avoided, resulting in the prevention of viscoelastic agent decomposition in the storage state. The mixture of viscoelastic agent and the dissolving agent is only generated when the plunger is longitudinally displaced from the storage state, and therefore only shortly before the mixture is injected into the eye. This allows the viscoelastic agent in the eye to perform its function before being decomposed by the dissolving agent.

[0006] Preferably, the viscoelastic agent contains hyaluronic acid and / or salts of hyaluronic acid, and the decomposing agent contains hyaluronidase, and / or preferably, the viscoelastic agent contains hydroxypropyl methylcellulose, and the decomposing agent contains cellulase, particularly exoglucanase and / or endoglucanase.

[0007] The syringe preferably includes a cannula through which the viscoelastic agent and the dissolving agent can be displaced from the syringe by longitudinal displacement of the plunger in the longitudinal direction of the syringe. In particular, a mixture of viscoelastic agent and dissolving agent can be displaced from the cannula.

[0008] Preferably, the syringe body includes a partition wall, wherein the viscoelastic chamber and the decomposing reagent chamber are arranged adjacent to each other in a direction perpendicular to the longitudinal direction of the syringe and separated from each other by means of the partition wall. Particularly preferred is that the syringe includes a mixing chamber arranged such that the viscoelastic and the decomposing reagent enter the mixing chamber when the plunger is displaced in the longitudinal direction of the syringe. In the mixing chamber, the viscoelastic and the decomposing reagent can mix and thus form a mixture. It is conceivable that, in the storage state, the mixing chamber does not contain viscoelastic and / or the decomposing reagent. This can be achieved, for example, by the syringe including a viscoelastic closure that prevents the flow of viscoelastic into the mixing chamber when the syringe is in the storage state, and that the viscoelastic closure can be opened by displacing the plunger from the storage state in the longitudinal direction of the syringe, and / or the syringe including a decomposing reagent closure that prevents the flow of decomposing reagent into the mixing chamber when the syringe is in the storage state, and that the decomposing reagent closure can be opened by displacing the plunger from the storage state in the longitudinal direction of the syringe. As an alternative or additional option, it is conceivable that, in the storage state, air or another gas is arranged in the mixing chamber, which prevents viscoelastic agents and / or decomposing agents from entering the mixing chamber.

[0009] Preferably, the mixing chamber is arranged such that when the plunger is displaced in the longitudinal direction of the syringe, the viscoelastic and the dissolving agent leave the mixing chamber together and then flow into the cannula. Therefore, the mixing chamber is located downstream of the viscoelastic chamber, downstream of the dissolving agent chamber, and upstream of the cannula, relative to the flow direction caused by the displacement of the plunger in the longitudinal direction of the syringe.

[0010] As an alternative to providing a mixing chamber, it is conceivable that the viscoelastic agent and the dissolving agent enter the cannula together and form a mixture there. In another example, where no mixing chamber is provided, it is conceivable that the cannula includes a first line into which the viscoelastic agent enters when the plunger is displaced in the longitudinal direction of the syringe and a second line into which the dissolving agent enters when the plunger is displaced in the longitudinal direction of the syringe, wherein the cannula is configured such that the mixture forms only after the viscoelastic agent and the dissolving agent have left the cannula.

[0011] The syringe preferably has a tip region and a body region, wherein the tip region is detachably connected to the body region, particularly by means of threads or by mounting the tip region onto the body region in a longitudinally displaceable manner, wherein a mixing chamber is arranged in the tip region, and a viscoelastic chamber and a decomposing reagent chamber are arranged in the body region.

[0012] The plunger preferably comprises a first plunger and a second plunger, the first plunger being configured to displace viscoelastic agent from a viscoelastic agent chamber, and the second plunger being separately arranged from the first plunger and configured to displace a dissolving agent from a dissolving agent chamber. Particularly preferred is that the second plunger has a predetermined fracture point. By causing the second plunger to fracture at the predetermined fracture point, the fractured portion of the second plunger can be removed from the syringe body. If the plunger is then displaced in the longitudinal direction of the syringe, only the viscoelastic agent is displaced from the cannula.

[0013] The syringe preferably includes a stopper arranged within the syringe body for displacement in the longitudinal direction of the syringe and for this purpose, actuation reagent chamber and viscoelastic chamber arranged continuously in the longitudinal direction of the syringe. In other words, the viscoelastic chamber is arranged downstream of the decomposition reagent chamber relative to the flow direction caused by displacement of the stopper in the longitudinal direction of the syringe. Furthermore, the viscoelastic chamber and decomposition reagent chamber are separated from each other by the stopper, which defines a conduit by which viscoelastic can flow from the viscoelastic chamber to the decomposition reagent chamber, and decomposition reagent can flow from the decomposition reagent chamber to the viscoelastic chamber. By displacing the stopper in the longitudinal direction of the syringe, the viscoelastic or decomposition reagent flows in the conduit in the opposite direction to the longitudinal direction of the syringe, and mixes with the decomposition reagent or viscoelastic after exiting the conduit. By displacing the stopper in the opposite direction to the longitudinal direction of the syringe, the viscoelastic or decomposition reagent flows in the conduit in the longitudinal direction of the syringe, and mixes with the decomposition reagent or viscoelastic after exiting the conduit. The viscoelastic agent and the dissolving agent can be mixed particularly well by shifting the stopper in the longitudinal direction of the syringe and then shifting it several times in the opposite direction.

[0014] The stopper preferably includes a valve configured to block the line in the storage state and open the line when the pressure difference between the viscoelastic chamber and the decomposing reagent chamber becomes too large. This prevents the viscoelastic and decomposing reagent from mixing in the storage state.

[0015] Preferably, the plunger is formed by an outer plunger and an inner plunger, the inner plunger being longitudinally displaceable within the outer plunger, wherein the stopper is secured to either the outer plunger or the inner plunger. Therefore, the stopper can be driven from outside the syringe body in a particularly simple manner in the longitudinal direction of the syringe and in the opposite direction to the longitudinal direction of the syringe.

[0016] The viscoelastic chamber is preferably arranged in the longitudinal direction of the syringe between the cannula and the decomposing reagent chamber. Attached Figure Description

[0017] The invention will now be explained in more detail with reference to the schematic drawings, in which: Figure 1 A longitudinal section through a first embodiment of a syringe is shown, the syringe having a viscoelastic chamber and a dissolving reagent chamber. Figure 2 A perspective view of a second embodiment of the viscoelastic agent chamber and the decomposing reagent chamber is shown. Figure 3 A perspective view of a third embodiment of the viscoelastic agent chamber and the decomposing reagent chamber is shown. Figure 4A perspective view of a first embodiment of the viscoelastic agent chamber and the decomposing reagent chamber is shown, as well as Figure 5 A longitudinal section through a second embodiment of the syringe is shown. Detailed Implementation

[0018] As from Figure 1 and Figure 5 As can be seen, the syringe 1 for eye manipulation includes a syringe body 3, a plunger 4, a viscoelastic chamber 6, and a dissolving reagent chamber 7. The plunger 4 is arranged in the syringe body 3 so as to be displaceable in the longitudinal direction 5 of the syringe. The viscoelastic is arranged in the viscoelastic chamber 6. The dissolving reagent chamber 7 is arranged separately from the viscoelastic chamber 6, wherein the dissolving reagent, configured to dissolve the viscoelastic, is arranged in the dissolving reagent chamber 7. The syringe 1 has a storage state and a use state, in which the viscoelastic and the dissolving reagent are arranged separately from each other, and particularly in their respective chambers 6 and 7, and the syringe 1 can enter the use state by longitudinal displacement of the plunger 4, and in the use state, the viscoelastic and the dissolving reagent are mixed together. By displacing the plunger 4 in the longitudinal direction 5 of the syringe from the storage state, a mixture comprising, and particularly consisting of, the viscoelastic and the dissolving reagent can be generated within the syringe 1. In particular, the syringe 1 can be designed such that mixing of the viscoelastic and the dissolving reagent does not occur in the storage state. The syringe 1 can be configured to inject the mixture into the eye. The term "use state" refers to any state in which the syringe plunger 4 has been displaced from the storage state in the longitudinal direction 5 of the syringe.

[0019] The viscoelastic agent may contain hyaluronic acid and / or salts of hyaluronic acid, and the dissolving agent may contain hyaluronidase, and / or the viscoelastic agent may contain hydroxypropyl methylcellulose, and the dissolving agent may contain cellulase, particularly exoglucanase and / or endoglucanase. Hyaluronidase is formulated to hydrolyze hyaluronic acid and / or salts of hyaluronic acid. Cellulase is formulated to hydrolyze hydroxypropyl methylcellulose. The viscoelastic agent may not contain the dissolving agent, and the dissolving agent may not contain the viscoelastic agent.

[0020] It is conceivable that the viscoelastic agent exists in liquid form. In a first exemplary solution forming the viscoelastic agent, hyaluronic acid and / or salts of hyaluronic acid can be dissolved in a solvent (e.g., water) for this purpose. The salt of hyaluronic acid can be, for example, sodium hyaluronate. Sodium hyaluronate can have, for example, an average molar mass in the range of 0.5 MDa to 4 MDa, particularly in the range of 0.5 MDa to 1.5 MDa. The concentration of sodium hyaluronate in the first solution can be, for example, in the range of 0.5% to 4.0% by mass, particularly in the range of 2.0% to 4.0% by mass. The viscoelastic agent can additionally contain auxiliary substances such as pH buffers, particularly phosphate buffers, NaCl, lidocaine, NaOH, sodium bicarbonate, and / or antioxidants. In a second exemplary solution forming the decomposition agent, hydroxypropyl methylcellulose can be dissolved in a solvent (e.g., water). Hydroxypropyl methylcellulose can, for example, have an average molar mass in the range of 10 kDa to 2000 kDa, particularly in the range of 50 kDa to 500 kDa. The concentration of hydroxypropyl methylcellulose in the viscoelastic agent can, for example, be in the range of 0.5% to 4.0% by mass, particularly in the range of 1.0% to 3.0% by mass. The viscoelastic agent may additionally contain auxiliary substances such as pH buffers, particularly phosphate buffers, NaCl, lidocaine, NaOH, sodium bicarbonate, and / or antioxidants.

[0021] It is conceivable that the decomposition reagent exists in liquid form. For example, for this purpose, in a third exemplary solution forming the decomposition reagent, hyaluronidase can be dissolved in a solvent (such as water). The concentration of hyaluronidase in the third solution can be in the range of 0.1 U / ml to 10 U / ml, particularly in the range of 0.5 U / ml to 2 U / ml. The decomposition reagent may additionally contain auxiliary substances, such as pH buffers, particularly phosphate buffers. In a fourth exemplary solution forming the decomposition reagent, cellulase can be dissolved in a solvent (such as water). The concentration of cellulase in the decomposition reagent can be in the range of 0.1 U / ml to 20 U / ml, particularly in the range of 0.5 U / ml to 5 U / ml. The decomposition reagent may additionally contain auxiliary substances, such as pH buffers, particularly phosphate buffers.

[0022] It is also conceivable that the decomposition reagent is a mixture of the first and second solutions. The volume ratio of the first solution to the second solution can be, for example, in the range of 1:100 to 100:1, particularly in the range of 1:10 to 10:1. In the case where the decomposition reagent is a mixture of the first and second solutions, it is conceivable that the decomposition reagent is a mixture of a third and a fourth solution. The volume ratio of the third solution to the fourth solution can be, for example, in the range of 1:100 to 100:1, particularly in the range of 1:10 to 10:1.

[0023] The volume ratio of viscoelastic agent to decomposing agent in syringe 1 can be set such that the increase in viscosity in the eye caused by injection of viscoelastic agent is reduced by 15% to 60%, and particularly by 25% to 50%, within 5 to 15 minutes.

[0024] Figure 1 and Figure 5 The syringe 1 is shown to include a cannula 2 through which viscoelastic and decomposing reagents can be displaced from the syringe 1 by longitudinal displacement of the plunger 4 in the longitudinal direction 5 of the syringe. The cannula 2 is positioned downstream of the viscoelastic chamber 6 and downstream of the decomposing reagent chamber 7 in the flow direction of the viscoelastic and / or decomposing reagents caused by the displacement of the plunger 4 in the longitudinal direction 5 of the syringe.

[0025] according to Figure 1 and Figure 4 In the first embodiment of the syringe 1 shown, the syringe body 3 may include a partition wall 16, wherein the viscoelastic chamber 6 and the decomposing reagent chamber 7 are arranged adjacent to each other in a direction perpendicular to the longitudinal direction 5 of the syringe and are separated from each other by means of the partition wall 16.

[0026] Figure 1The syringe 1 is shown to include a mixing chamber 8, which is arranged such that when the plunger 4 is displaced in the longitudinal direction 5 of the syringe, the viscoelastic agent and the decomposing agent enter the mixing chamber 8. Therefore, a mixture can be formed in the mixing chamber 8. Furthermore, the mixing chamber 8 can be arranged such that when the plunger 4 is displaced in the longitudinal direction 5 of the syringe, the viscoelastic agent and the decomposing agent leave the mixing chamber 8 together and then flow into the cannula 2; that is, the mixing chamber 8 is arranged downstream of the viscoelastic agent chamber 6, downstream of the decomposing agent chamber 7, and upstream of the cannula 2, relative to the flow direction. The mixing chamber 8 may include a first mixing chamber opening 17, through which, in use, the mixing chamber 8 is fluidly connected to the viscoelastic agent chamber 6. The mixing chamber 8 may include a second mixing chamber opening 18, through which, in use, the mixing chamber 8 is fluidly connected to the decomposing agent chamber 7. It is contemplated that the first mixing chamber opening 17 is arranged spaced apart from the second mixing chamber opening 18. The mixing chamber 8 may include a third mixing chamber opening 19, which is fluidly connected to the cannula 2. The third mixing chamber opening 19 may be arranged to be spaced apart from the first mixing chamber opening 17 and the second mixing chamber opening 18.

[0027] It is conceivable that the syringe 1 includes a viscoelastic seal that, when the syringe 1 is in the storage state, prevents the viscoelastic from flowing from the viscoelastic chamber 6 into the mixing chamber 8. This viscoelastic seal can be opened by displacing the plunger 4 in the longitudinal direction 5 of the syringe from the storage state. This is achieved by preventing the mixing of the viscoelastic and the decomposing agent in the storage state. Alternatively, it is conceivable that the syringe 1 includes a decomposing agent seal that, when the syringe 1 is in the storage state, prevents the decomposing agent from flowing from the decomposing agent chamber 7 into the mixing chamber 8. This decomposing agent seal can be opened by displacing the plunger 4 in the longitudinal direction 5 of the syringe from the storage state.

[0028] The syringe 1 may have a tip region 9 and a body region 10, wherein the tip region 9 is detachably connected to the body region 10, wherein a mixing chamber 8 is arranged in the tip region 9, and a viscoelastic agent chamber 6 and a decomposing reagent chamber 7 are arranged in the body region 10. Figure 1 In the diagram, the dashed line indicates the boundary between the tip region 9 and the body region 10. To allow the tip region 9 to be detachably connected to the body region 10, the syringe 1 may, for example, have threads, or the tip region 9 may be arranged on the body region 10 in a longitudinally displaceable manner.

[0029] It can be envisioned that the cross-section of the decomposing reagent chamber 7 in a plane whose normal is parallel to the longitudinal direction 5 of the syringe is smaller than the cross-section of the viscoelastic agent chamber 6 in that plane. This allows the decomposing reagent to be supplied in a smaller volume than the viscoelastic agent. In particular, the cross-section of the decomposing reagent chamber 7 is less than or equal to 50% of the cross-section of the viscoelastic agent chamber 6.

[0030] As from Figure 1 and Figure 2 It can be seen that the plunger 4 may include a first plunger 11 and a second plunger 12. The first plunger is configured to displace the viscoelastic agent from the viscoelastic agent chamber 6, and the second plunger is separately arranged from the first plunger 11 and configured to displace the decomposing agent from the decomposing agent chamber 7. In this case, the first plunger 11 defines the viscoelastic agent chamber 6, and the second plunger 12 defines the decomposing agent chamber 7. It is conceivable that the plunger 4 includes a thumb rest 15, which forms the end of the plunger 4 opposite to the viscoelastic agent chamber 6. The first plunger 11 and the second plunger 12 can be fastened to the thumb rest 15. Therefore, the first plunger 11 and the second plunger 12 can be displaced simultaneously by pressing the thumb rest 15. It is conceivable that the first plunger 11 has a first plunger thickening portion 13, which forms the end of the first plunger 11 opposite to the thumb rest 15. Alternatively, it can be envisioned that the second plunger 12 has a second plunger thickening portion 14, which forms the end of the second plunger 12 opposite to the thumb support 15.

[0031] It is conceivable that the second plunger 12 has a predetermined break point. The second plunger 12 can break at the predetermined break point, and a portion of the second plunger 12, including the longitudinal end of the second plunger 12 opposite to the thumb rest 15, can be removed from the syringe body 2. Alternatively, it is conceivable that the second plunger 12 is not directly or indirectly fastened to the thumb rest 15, but only the first plunger 12 is fastened to the thumb rest 15, resulting in the second plunger 12 being removable from the syringe body 2. It is also conceivable that the thumb rest 15 includes a through-hole through which the second plunger 12 extends. In this case, the second plunger 12 may include a locking mechanism having an unlocked state and a locked state, in which the second plunger 12 can slide through the through-hole, and in which the second plunger 12 is fastened to the thumb rest 15. In the locked state, only the viscoelastic is expelled from the syringe 1 by the longitudinal displacement of the plunger 4, while in the unlocked state, both the viscoelastic and the dissolving agent are expelled from the syringe 1 by the longitudinal displacement of the plunger 4. This allows, for example, the viscoelastic to be injected first alone, and then the viscoelastic to be injected together with the dissolving agent. For example, the locking mechanism can be formed by teeth on the second portion of the plunger 12, which do not engage with the thumb rest 15 in the unlocked state, but engage with the thumb rest 15 in the locked state. For example, the teeth can be engaged by rotation of the second portion of the plunger 12.

[0032] Figure 1 and Figure 4 A first embodiment of a viscoelastic chamber 6 and a decomposing reagent chamber 7 is shown, wherein the decomposing reagent chamber 7 is not surrounded by the viscoelastic chamber 6, but is arranged completely laterally to the viscoelastic chamber 6 in a direction transverse to the longitudinal direction 5 of the syringe. Figure 2 A second embodiment of a viscoelastic agent chamber 6 and a decomposing reagent chamber 7 is shown, wherein the viscoelastic agent chamber 6 surrounds the decomposing reagent chamber 7. Figure 3 A third embodiment of the viscoelastic agent chamber 6 and the decomposing reagent chamber 7 is shown, wherein a plurality of decomposing reagent chambers 7 are provided. It is conceivable that a corresponding second-part plunger 12 is provided for each decomposing reagent chamber 7.

[0033] according to Figure 5In a second embodiment of the syringe 1 shown, the syringe 1 may include a stopper 23 disposed within the syringe body 3 so as to be displaceable in the longitudinal direction 5 of the syringe and to be actuated from outside the syringe body 3 for this purpose, wherein the decomposing reagent chamber 7 and the viscoelastic chamber 6 are arranged continuously in the longitudinal direction 5 of the syringe. In other words, the viscoelastic chamber 6 is disposed downstream of the decomposing reagent chamber 7 relative to the flow direction caused by the displacement of the plunger 4 in the longitudinal direction 5 of the syringe. Furthermore, the viscoelastic chamber 6 and the decomposing reagent chamber 7 are separated from each other by means of the stopper 23, which defines a conduit 24 by means of which viscoelastic can flow from the viscoelastic chamber 6 to the decomposing reagent chamber 7, and decomposing reagent can flow from the decomposing reagent chamber 7 to the viscoelastic chamber 6. The stopper 23 may include a valve 28 configured to block the conduit 24 in a stored state and to open the conduit 24 when the pressure difference between the viscoelastic chamber 6 and the decomposing reagent chamber 7 is too large. Therefore, syringe 1 is designed so that mixing of the viscoelastic agent and the decomposing agent does not occur in the storage state. If the pressure in the viscoelastic agent chamber 6 is higher than the pressure in the decomposing agent chamber 7 by a first pressure difference, valve 28 opens line 24. If the pressure in the decomposing agent chamber 7 is higher than the pressure in the viscoelastic agent chamber 6 by a second pressure difference, valve 28 opens line 24. It is conceivable that the first pressure difference is equal to the second pressure difference. Alternatively, it is also conceivable that valve 28 is a membrane that tears when the pressure difference between the viscoelastic agent chamber 6 and the decomposing agent chamber 7 is too large.

[0034] Figure 5 The plunger 4 is shown to be formed of an outer plunger 21 and an inner plunger 22, the inner plunger being longitudinally displaceable within the outer plunger 21, wherein a stopper 23 is fastened to the inner plunger 22. Alternatively, it is conceivable that the stopper 23 is fastened to the outer plunger 21. By fastening the stopper 23 to either the inner or outer plunger 22, the stopper 23 can be driven from outside the syringe body 2 in the syringe longitudinal direction 5 or in the opposite direction to the syringe longitudinal direction 5. It is conceivable that the outer plunger 21 includes an outer plunger thumb rest 29, which is a thickened portion of the outer plunger 21 at its longitudinal end opposite to the cannula 2. Additionally, the inner plunger 22 may include an inner plunger thumb rest 30, which is a thickened portion of the inner plunger 22 at its longitudinal end opposite to the cannula 2, and this inner plunger thumb rest is arranged outside the outer plunger 21 in both the storage and use states.

[0035] The tubing 24 may include a first sub-tubing 25 and a second sub-tubing 26, which communicate with one of the viscoelastic chamber 6 and the decomposing reagent chamber 7 located on the side of the stopper 23 opposite to the cannula 2. The first sub-tubing 25 and the second sub-tubing 26 may extend from different sides of the inner plunger 22 in a direction perpendicular to the longitudinal direction 5 of the syringe to one of the viscoelastic chamber 6 and the decomposing reagent chamber 7 located on the side of the stopper 23 opposite to the cannula 2 (see [link to syringe description]). Figure 5 Additionally, line 24 may include a third sub-line 27 leading to one of the viscoelastic chamber 6 and the decomposing reagent chamber 7, which has an opening on the side of the stopper 23 facing the insertion tube 2, wherein the first sub-line 25 and the second sub-line 26 lead to the third sub-line 27. A valve 28 may be arranged in the third sub-line 27.

[0036] The viscoelastic chamber 6 can be arranged in the longitudinal direction 5 of the syringe between the cannula 2 and the disintegrating reagent chamber 7 (see...). Figure 5 ).

[0037] Then, by means of the inner plunger 22, the stopper 23 is displaced in the longitudinal direction 5 of the syringe, and the viscoelastic flows through the tubing 24 in the opposite direction to the longitudinal direction 5 of the syringe into the dissolving reagent chamber 7, where it mixes with the dissolving reagent. It is conceivable that the outer plunger 21 is displaced in the opposite direction to the longitudinal direction 5 of the syringe to compensate for the volume of the inner plunger 21 in the viscoelastic chamber 7. If the stopper 23 is then displaced in the opposite direction to the longitudinal direction 5 of the syringe by means of the inner plunger 22, the mixture of viscoelastic and dissolving reagent flows through the tubing 24 in the longitudinal direction 5 of the syringe into the viscoelastic chamber 6. Simultaneously, the outer plunger 21 can be displaced in the longitudinal direction 5 of the syringe to compensate for the volume of the inner plunger 22 in the dissolving reagent chamber 7.

[0038] List of reference numerals 1. Syringe 2. Intubation 3. Syringe body 4. Plunger 5. Syringe longitudinal direction 6 Viscoelastic chamber 7. Decomposition reagent chamber 8 Mixing Chambers 9. End area 10. Body Region 11 Part One Plunger 12 Part Two Plunger 13 Thickened section of the first plunger 14. Thickened section of the second plunger 15. Thumb support 16. Partition wall 17. First mixing chamber opening 18. Second mixing chamber opening 19. Opening of the third mixing chamber 21. External plunger 22 Inner plunger 23 Block 24 pipelines 25 First Sub-pipeline 26 Second Sub-pipeline 27 Third Sub-pipeline 28 valves 29. External plunger thumb support 30. Inner plunger thumb support.

Claims

1. A syringe for eye manipulation, the syringe comprising: The syringe body (3); a plunger (4) arranged in the syringe body (3) so as to be displaced in the longitudinal direction (5) of the syringe; a viscoelastic chamber (6) in which viscoelastic is disposed; and a decomposing reagent chamber (7) arranged separately from the viscoelastic chamber (6) and in which a decomposing reagent configured to decompose the viscoelastic is disposed, wherein the syringe (1) has a storage state and a use state, wherein in the storage state the viscoelastic and the decomposing reagent are arranged separately from each other, the syringe (1) can enter the use state by longitudinal displacement of the plunger (4), and in the use state the viscoelastic and the decomposing reagent are mixed together.

2. The syringe as claimed in claim 1, wherein, The viscoelastic agent contains hyaluronic acid and / or salts of hyaluronic acid, and the decomposing agent contains hyaluronidase, and / or wherein the viscoelastic agent contains hydroxypropyl methylcellulose, and the decomposing agent contains cellulase, particularly exoglucanase and / or endoglucanase.

3. The syringe as claimed in claim 1 or 2, wherein, The syringe (1) includes a cannula (2) through which the viscoelastic agent and the disintegrating agent can be displaced from the syringe (1) by the longitudinal displacement of the plunger (4) in the longitudinal direction (5) of the syringe.

4. The syringe as claimed in claim 3, wherein, The syringe body (3) includes a partition wall (16), wherein the viscoelastic chamber (6) and the decomposing reagent chamber (7) are arranged adjacent to each other in a direction perpendicular to the longitudinal direction (5) of the syringe and are separated from each other by means of the partition wall (16).

5. The syringe as claimed in claim 4, wherein, The syringe (1) includes a mixing chamber (8) arranged such that when the plunger (4) is displaced in the longitudinal direction (5) of the syringe, the viscoelastic and the decomposing agent enter the mixing chamber (8), and in particular, the mixing chamber (8) is arranged such that when the plunger (4) is displaced in the longitudinal direction (5) of the syringe, the viscoelastic and the decomposing agent leave the mixing chamber (8) together and then flow into the cannula (2).

6. The syringe as claimed in claim 5, wherein, The syringe (1) has a tip region (9) and a body region (10), wherein the tip region (9) is detachably connected to the body region (10), wherein the mixing chamber (8) is arranged in the tip region (9), and the viscoelastic chamber (6) and the decomposing reagent chamber (7) are arranged in the body region (10).

7. The syringe as claimed in any one of claims 4 to 6, wherein, The plunger (4) includes a first plunger (11) and a second plunger (12), the first plunger being configured to displace the viscoelastic agent from the viscoelastic agent chamber (6), the second plunger being separately arranged from the first plunger (11) and configured to displace the decomposing agent from the decomposing agent chamber (7), wherein the second plunger (12) has a predetermined breaking point.

8. The syringe as claimed in claim 3, wherein, The syringe (1) includes a stopper (23) disposed in the syringe body (3) so as to be displaced in the longitudinal direction (5) of the syringe and to be driven from outside the syringe body (3) for this purpose, wherein the decomposing reagent chamber (7) and the viscoelastic chamber (6) are arranged continuously in the longitudinal direction (5) of the syringe and separated from each other by means of the stopper (23), the stopper defining a line (24) by means of which the viscoelastic can flow from the viscoelastic chamber (6) to the decomposing reagent chamber (7) and the decomposing reagent can flow from the decomposing reagent chamber (7) to the viscoelastic chamber (6).

9. The syringe of claim 8, wherein, The stopper (23) includes a valve (28) configured to block the line (24) in the storage state and open the line (24) when the pressure difference between the viscoelastic chamber (6) and the decomposing reagent chamber (7) is too large.

10. The syringe as claimed in claim 8 or 9, wherein, The plunger (4) is formed by an outer plunger (21) and an inner plunger (22), the inner plunger being longitudinally displaceable within the outer plunger (21), wherein the stopper (23) is fastened to the outer plunger (21) or to the inner plunger (22).